查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1615370

真菌感染疾病診斷市場：按類型、診斷方法、最終用戶分類 - 全球預測 2025-2030

Fungal Infections Diagnosis Market by Type, Diagnostic Method, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

真菌感染疾病診斷市場2023年估值為20.9億美元，預計到2024年將達到22.3億美元，複合年成長率為6.96%，到2030年預計將達到33.5億美元。

真菌感染疾病診斷市場的範圍包括診斷方法，包括分子診斷、免疫診斷和其他傳統技術，旨在識別醫療環境中的真菌病原體。由於免疫力缺乏低下患者數量的增加和影響病原體傳播的氣候變遷等因素，不同人群中真菌感染疾病的發病率不斷增加，從而產生了這一需求。最終用途涵蓋醫院、診所和實驗室，包括醫療服務提供者、研究人員、製藥公司等。關鍵的成長要素包括診斷技術的進步、意識的提高以及政府對感染疾病控制的資助。快速、非侵入性診斷工具的開發以及人工智慧和機器學習的整合用於預測診斷存在潛在的機會。公司應專注於擴大其 POCT（就地檢驗）能力。 POCT 可以快速診斷，在資源匱乏的地區特別有用。挑戰包括先進診斷系統的高成本、發展中地區獲得醫療保健的機會有限，以及由於症狀與其他疾病重疊而識別真菌病原體的複雜性。創新是可能的，例如攜帶式診斷技術、用於早期檢測的新型生物標記物以及可以提高準確性同時降低人事費用的自動化系統。對闡明真菌抗藥性機制和提高現有診斷工具靈敏度的研究可能會進一步推動市場的成熟。目前市場充滿活力，生技公司的興趣日益濃厚，醫療機構與高科技公司之間的合作不斷加強，以開發智慧診斷。當公司在這個市場上航行時，他們可能會受益於醫學教育的戰略重點以及與政府機構和非政府組織合作以提高診斷的可及性。解決負擔能力問題並加快新診斷解決方案的核准流程可以緩解限制並加速成長。

主要市場統計
基準年[2023] 20.9億美元
預測年份 [2024] 22.3億美元
預測年份 [2030] 33.5億美元
複合年成長率（%） 6.96%

市場動態：揭示快速發展的真菌感染疾病診斷市場的關鍵市場洞察

供需的動態交互作用正在改變真菌感染疾病診斷市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 真菌感染疾病的流行和有效診斷方法的需求
    • 政府提高真菌感染疾病管理意識的舉措
    • 真菌傳染病檢查系列獲得有利核准
  • 市場限制因素
    • 真菌感染疾病分子和遺傳學診斷的複雜性
  • 市場機會
    • 分子和照護現場診斷技術的進步
    • 遠距皮膚科在真菌感染疾病檢測和診斷的潛力
  • 市場問題
    • 與診斷方法不準確相關的局限性

波特五力：引領真菌感染疾病診斷市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架描述了評估公司競爭和探索策略機會的清晰方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解真菌感染疾病診斷市場的外部影響

外部宏觀環境因素在塑造真菌感染疾病診斷市場的績效動態發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析：了解真菌感染疾病診斷市場的競爭格局

對真菌感染疾病診斷市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、細分和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣：真菌感染疾病診斷市場供應商的績效評估

FPNV定位矩陣是評估真菌感染疾病診斷市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議：繪製真菌感染疾病診斷市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，真菌感染疾病診斷市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

該報告對涵蓋關鍵焦點細分市場的市場進行了全面分析。

1. 市場滲透率：詳細檢視當前市場環境，主要企業的廣泛資料，評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有細分市場的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策。

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品和地區提供最佳投資機會？

3.塑造市場的關鍵技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 真菌感染疾病的流行和有效診斷方法的需求
      • 政府提高真菌感染疾病管理意識的舉措
      • 真菌傳染病檢查系列核准
    • 抑制因素
      • 真菌感染疾病分子遺傳學診斷的複雜性
    • 機會
      • 分子診斷技術和照護現場診斷技術的進展
      • 遠距皮膚病學在檢測和診斷真菌感染疾病的潛力
    • 任務
      • 與診斷方法不準確相關的局限性
  • 市場區隔分析
    • 類型：由於患者免疫力下降而導致機會性真菌感染疾病的發生率增加
    • 診斷方法：細胞和分子生物學的進步導致採用分子診斷方法來檢測感染。
    • 最終用戶：不斷上漲的醫療成本提高了醫院診斷真菌感染疾病的重要性。
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

第6章真菌感染疾病診斷市場：按類型

  • 介紹
  • 地方性真菌感染疾病
  • 機會性真菌感染疾病
  • 皮下真菌感染疾病
  • 表層真菌感染疾病
  • 全身性真菌感染疾病

第7章真菌感染疾病診斷市場：依診斷方法

  • 介紹
  • 抗原測試
  • 皮膚科檢查
  • 組織病理學
  • 微生物培養
  • 分子診斷
  • 血清學

第8章真菌感染疾病診斷市場：依最終用戶分類

  • 介紹
  • 醫院
  • 照護現場
  • 研究所
  • 專科診所

第9章北美和南美真菌感染疾病診斷市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區真菌感染疾病診斷市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲真菌感染疾病診斷市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • 明尼蘇達大學研究人員成功測試了治療真菌性腦膜炎的新抗真菌療法
    • Applied BioCode 宣布推出研究真菌組合檢測
    • 亞利桑那大學的研究人員幫助追蹤亞利桑那州污水中的致命真菌
  • 戰略分析和建議

公司名單

  • Abbott Laboratories
  • Alexion Pharmaceuticals, Inc.
  • Amgen Inc.
  • Associates of Cape COD, Inc. by Seikagaku Group company
  • Astellas Pharma Inc.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • BioMerieux SA
  • Bruker Corporation
  • Danaher Corporation
  • Eli Lilly and Company
  • ELITech Group
  • Eurofins Viracor, LLC
  • F. Hoffmann-La Roche AG
  • Hologic, Inc.
  • Immununexpress Inc.
  • IMMY
  • InBios International, Inc.
  • Laboratory Corporation of America Holdings
  • Merck KGaA
  • Norgen BIoTek Corp.
  • PerkinElmer, Inc.
  • Polysciences, Inc.
  • Qiagen NV
  • Siemens Healthineers
  • Takeda Pharmaceutical Company Limited
  • Thermo Fisher Scientific Inc.
Product Code: MRR-346757DFA1E9

The Fungal Infections Diagnosis Market was valued at USD 2.09 billion in 2023, expected to reach USD 2.23 billion in 2024, and is projected to grow at a CAGR of 6.96%, to USD 3.35 billion by 2030.

The scope of the fungal infections diagnosis market encompasses diagnostic methods, including molecular diagnostics, immunodiagnostics, and other traditional techniques, aimed at identifying fungal pathogens in medical settings. The necessity arises from the rising incidence of fungal infections across various populations, attributed to factors like increasing immunocompromised patients and climate change affecting pathogen spread. Application extends to hospitals, clinics, and laboratories, with end-use scope involving healthcare providers, researchers, and pharmaceutical companies. Key growth influencers include advancements in diagnostic technologies, increasing awareness, and government funding for infectious disease management. Potential opportunities lie in the development of rapid, non-invasive diagnostic tools and the integration of AI and machine learning for predictive diagnostics. Companies should focus on expanding POCT (point-of-care testing) capabilities, which can provide quicker diagnoses and are particularly beneficial in under-resourced regions. Challenges include high costs of advanced diagnostic systems, limited access to healthcare in developing regions, and the complexity of fungal pathogen identification due to overlapping symptoms with other diseases. Innovations can be directed towards portable diagnostic technologies, novel biomarkers for early detection, and automated systems that can enhance accuracy while reducing labor costs. Research on understanding the resistance mechanisms of fungal strains and improving the sensitivity of existing diagnostic tools could further drive market sophistication. The market is currently dynamic, with a growing interest from biotech firms and increasing collaborations between healthcare organizations and tech companies to develop smart diagnostics. As businesses navigate this market, a strategic focus on healthcare education and partnerships with governmental and non-governmental organizations to enhance diagnostic accessibility could be beneficial. Addressing affordability and speeding up approval processes for new diagnostic solutions could mitigate limitations and accelerate growth.

KEY MARKET STATISTICS
Base Year [2023] USD 2.09 billion
Estimated Year [2024] USD 2.23 billion
Forecast Year [2030] USD 3.35 billion
CAGR (%) 6.96%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Fungal Infections Diagnosis Market

The Fungal Infections Diagnosis Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Prevalence of fungal infections and need for effective diagnosis methods
    • Government initiatives promoting awareness of fungal infection management
    • Favorable approvals for fungal infection test series
  • Market Restraints
    • Complexity of molecular and genetic fungal infection diagnosis
  • Market Opportunities
    • Advancements in molecular and point-of-care diagnosis technologies
    • Potential of teledermatology in fungal infection detection and diagnosis
  • Market Challenges
    • Limitations associated with the inaccuracy of the diagnostic methods

Porter's Five Forces: A Strategic Tool for Navigating the Fungal Infections Diagnosis Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Fungal Infections Diagnosis Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Fungal Infections Diagnosis Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Fungal Infections Diagnosis Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Fungal Infections Diagnosis Market

A detailed market share analysis in the Fungal Infections Diagnosis Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Fungal Infections Diagnosis Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Fungal Infections Diagnosis Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Fungal Infections Diagnosis Market

A strategic analysis of the Fungal Infections Diagnosis Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Fungal Infections Diagnosis Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Alexion Pharmaceuticals, Inc., Amgen Inc., Associates of Cape COD, Inc. by Seikagaku Group company, Astellas Pharma Inc., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., BioMerieux SA, Bruker Corporation, Danaher Corporation, Eli Lilly and Company, ELITech Group, Eurofins Viracor, LLC, F. Hoffmann-La Roche AG, Hologic, Inc., Immununexpress Inc., IMMY, InBios International, Inc., Laboratory Corporation of America Holdings, Merck KGaA, Norgen Biotek Corp., PerkinElmer, Inc., Polysciences, Inc., Qiagen N.V., Siemens Healthineers, Takeda Pharmaceutical Company Limited, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Fungal Infections Diagnosis Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Endemic Fungal Infections, Opportunistic Fungal Infections, Subcutaneous Fungal Infections, Superficial Fungal Infections, and Systemic Fungal Infections.
  • Based on Diagnostic Method, market is studied across Antigen Testing, Dermatological Examination, Histopathology, Microbiological Culture, Molecular Diagnostics, and Serology.
  • Based on End-User, market is studied across Hospitals, Point-of-Care Settings, Research Institutions, and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of fungal infections and need for effective diagnosis methods
      • 5.1.1.2. Government initiatives promoting awareness of fungal infection management
      • 5.1.1.3. Favorable approvals for fungal infection test series
    • 5.1.2. Restraints
      • 5.1.2.1. Complexity of molecular and genetic fungal infection diagnosis
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in molecular and point-of-care diagnosis technologies
      • 5.1.3.2. Potential of teledermatology in fungal infection detection and diagnosis
    • 5.1.4. Challenges
      • 5.1.4.1. Limitations associated with the inaccuracy of the diagnostic methods
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Growing incidences of opportunistic fungal infections due to weakened immune system in patients
    • 5.2.2. Diagnostic Method: Advancements in cellular and molecular biology leading to the adoption of molecular diagnostics for infection detection
    • 5.2.3. End-user: Expanding healthcare expenditure leading to growth and significance of hospitals for fungal infection diagnosis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Fungal Infections Diagnosis Market, by Type

  • 6.1. Introduction
  • 6.2. Endemic Fungal Infections
  • 6.3. Opportunistic Fungal Infections
  • 6.4. Subcutaneous Fungal Infections
  • 6.5. Superficial Fungal Infections
  • 6.6. Systemic Fungal Infections

7. Fungal Infections Diagnosis Market, by Diagnostic Method

  • 7.1. Introduction
  • 7.2. Antigen Testing
  • 7.3. Dermatological Examination
  • 7.4. Histopathology
  • 7.5. Microbiological Culture
  • 7.6. Molecular Diagnostics
  • 7.7. Serology

8. Fungal Infections Diagnosis Market, by End-User

  • 8.1. Introduction
  • 8.2. Hospitals
  • 8.3. Point-of-Care Settings
  • 8.4. Research Institutions
  • 8.5. Specialty Clinics

9. Americas Fungal Infections Diagnosis Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Fungal Infections Diagnosis Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Fungal Infections Diagnosis Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. University of Minnesota Research Team Successfully Tests New Antifungal Therapy For Fungal Meningitis
    • 12.3.2. Applied BioCode Announces the Launch of the Fungal Panel Assay for Research Use
    • 12.3.3. University of Arizona Researchers to Help Track Deadly Fungus in Arizona Wastewater
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Alexion Pharmaceuticals, Inc.
  • 3. Amgen Inc.
  • 4. Associates of Cape COD, Inc. by Seikagaku Group company
  • 5. Astellas Pharma Inc.
  • 6. Becton, Dickinson and Company
  • 7. Bio-Rad Laboratories, Inc.
  • 8. BioMerieux SA
  • 9. Bruker Corporation
  • 10. Danaher Corporation
  • 11. Eli Lilly and Company
  • 12. ELITech Group
  • 13. Eurofins Viracor, LLC
  • 14. F. Hoffmann-La Roche AG
  • 15. Hologic, Inc.
  • 16. Immununexpress Inc.
  • 17. IMMY
  • 18. InBios International, Inc.
  • 19. Laboratory Corporation of America Holdings
  • 20. Merck KGaA
  • 21. Norgen Biotek Corp.
  • 22. PerkinElmer, Inc.
  • 23. Polysciences, Inc.
  • 24. Qiagen N.V.
  • 25. Siemens Healthineers
  • 26. Takeda Pharmaceutical Company Limited
  • 27. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. FUNGAL INFECTIONS DIAGNOSIS MARKET RESEARCH PROCESS
  • FIGURE 2. FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. FUNGAL INFECTIONS DIAGNOSIS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. FUNGAL INFECTIONS DIAGNOSIS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. FUNGAL INFECTIONS DIAGNOSIS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. FUNGAL INFECTIONS DIAGNOSIS MARKET DYNAMICS
  • TABLE 7. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY ENDEMIC FUNGAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY OPPORTUNISTIC FUNGAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SUBCUTANEOUS FUNGAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SUPERFICIAL FUNGAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SYSTEMIC FUNGAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY ANTIGEN TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DERMATOLOGICAL EXAMINATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY HISTOPATHOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MICROBIOLOGICAL CULTURE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SEROLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY POINT-OF-CARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 45. ASIA-PACIFIC FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. ASIA-PACIFIC FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 49. AUSTRALIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. AUSTRALIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 51. AUSTRALIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. CHINA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. CHINA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 54. CHINA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 55. INDIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. INDIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 57. INDIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 58. INDONESIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. INDONESIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 60. INDONESIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 61. JAPAN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. JAPAN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 63. JAPAN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 64. MALAYSIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. MALAYSIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 66. MALAYSIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 67. PHILIPPINES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. PHILIPPINES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 69. PHILIPPINES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 70. SINGAPORE FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. SINGAPORE FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 72. SINGAPORE FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. SOUTH KOREA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. SOUTH KOREA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 75. SOUTH KOREA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 76. TAIWAN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. TAIWAN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 78. TAIWAN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. THAILAND FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. THAILAND FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 81. THAILAND FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 82. VIETNAM FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. VIETNAM FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 84. VIETNAM FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 89. DENMARK FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. DENMARK FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 91. DENMARK FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 92. EGYPT FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. EGYPT FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 94. EGYPT FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. FINLAND FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. FINLAND FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 97. FINLAND FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 98. FRANCE FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. FRANCE FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 100. FRANCE FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 101. GERMANY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. GERMANY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 103. GERMANY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 104. ISRAEL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. ISRAEL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 106. ISRAEL FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 107. ITALY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. ITALY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 109. ITALY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 110. NETHERLANDS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. NETHERLANDS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 112. NETHERLANDS FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 113. NIGERIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. NIGERIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 115. NIGERIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 116. NORWAY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. NORWAY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 118. NORWAY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 119. POLAND FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. POLAND FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 121. POLAND FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. QATAR FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. QATAR FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 124. QATAR FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 125. RUSSIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. RUSSIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 127. RUSSIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 128. SAUDI ARABIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. SAUDI ARABIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 130. SAUDI ARABIA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 131. SOUTH AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. SOUTH AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 133. SOUTH AFRICA FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 134. SPAIN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. SPAIN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 136. SPAIN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 137. SWEDEN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. SWEDEN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 139. SWEDEN FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 140. SWITZERLAND FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. SWITZERLAND FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 142. SWITZERLAND FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 143. TURKEY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. TURKEY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 145. TURKEY FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED ARAB EMIRATES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED ARAB EMIRATES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 148. UNITED ARAB EMIRATES FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 149. UNITED KINGDOM FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. UNITED KINGDOM FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
  • TABLE 151. UNITED KINGDOM FUNGAL INFECTIONS DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 152. FUNGAL INFECTIONS DIAGNOSIS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 153. FUNGAL INFECTIONS DIAGNOSIS MARKET, FPNV POSITIONING MATRIX, 2023